Flurpiridaz F 18

An expansion in Ireland falls under the purview of GE HealthCare’s pharmaceutical diagnostics arm, which produces radiopharmaceuticals in addition to molecular imaging agents and contrast media.\n Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle.The company is pumping $138 million into its Carrigtwohill fill-finish site in County Cork, Ireland, to build a new facility that will help deliver 25 million more contrast media doses per year by the end of 2027.The 3,000-square-meter (32,292-square-foot) manufacturing plant will be designed to help produce both commercial products and those from GE HealthCare’s pipeline, the company said. The site will come equipped with solution preparation vessels, multifunctional power handling systems, a new filling line and autoclaves—all underpinned by automation systems.The expansion falls under the purview of its pharmaceutical diagnostics arm, which produces radiopharmaceuticals in addition to molecular imaging agents and contrast media. To hear GE HealthCare tell it, the global demand for iodine-based contrast media—injections that enhance the visualization of organs, blood vessels and tissues during real-time medical imaging—is expected to double within the next decade due to an aging population and the growing prevalence of chronic disorders.Aside from the site in Carrigtwohill, GE HealthCare also cranks out contrast media at fill-finish production campuses in Shanghai and Oslo.“This expansion strengthens our longstanding presence in Cork, where we have a highly skilled team, access to leading talent in the pharmaceutical industry, strong distribution links around the world and a great partnership with IDA Ireland,” Eugene Barrett, site leader and managing director for GE HealthCare Ireland, said in a statement. “First doses from our new facility are expected by the end of 2027 and we are proud of the impact our site will continue to make for patients around the world.” GE Healthcare had a busy end to 2024.In addition to picking up an FDA nod for its PET scan imaging tracer Flyrcado, the company also unveiled its new artificial-intelligence-powered Pristina Via mammography system, inked an AI collaboration with RadNet and announced plans to take full control of radiopharmaceutical and molecular imaging firm Nihon Medi-Physics.More recently, GE revealed earlier this month at the J.P. Morgan Healthcare Conference that it’s launching a new imaging research collaboration with the University of California, San Francisco. The team-up will see the partners work to develop automated imaging methods, including MRI techniques, for neurodegenerative diseases and cancer.Elsewhere, multiple pharma majors have made manufacturing inroads into Ireland in recent years.Last September, Eli Lilly revealed an $1.8 billion investment to expand production capacity at a pair of Irish plants in Limerick and Kinsale. The Limerick plant, which is under construction, will help crank out biologic active ingredients, including those for Lilly’s Alzheimer’s drug Kisunla, while the Kinsale facility produces the drugmaker’s tirzepatide products Mounjaro and Zepbound.Plus, Bristol Myers Squibb in early 2024 blueprinted a $400-million investment at its Dublin 15 Cruiserath campus in Ireland, which will both help produce existing medicines and serve as a “launch excellence facility.” The project, which BMS plans to wrap up by 2026, is expected to create 350 new jobs concurrent with the plant build-out.Multiple other large drugmakers like Pfizer, Novo Nordisk and Astellas also maintain manufacturing footprints in the country. 

CHICAGO--( BUSINESS WIRE )--At the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from Dec. 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) will exhibit more than 40 innovations, including several key artificial intelligence (AI)-enabled technologies to optimize patient care and increase operational efficiencies. GE HealthCare products are designed to increase efficiency and help seamlessly integrate data to support precision care across multiple care pathways. These innovations represent the company’s broader AI and digital strategy, which is focused on integrating AI into medical devices, building AI applications that enhance decision-making across the care journey and disease states, and using AI to support better outcomes. According to surveys of over 8,000 radiology professionals included in a 2024 report from the American Society of Radiologic Technologists , more than half reported feeling emotionally exhausted, and 57% felt underappreciated on the job. “Radiologists face challenges that continue to grow, placing extraordinary pressure on an indispensable part of the healthcare imaging and diagnosis journey,” said Peter Arduini, CEO of GE HealthCare. “GE HealthCare is on a mission to deliver technologies that address radiologists’ biggest areas of concern. We are innovating new solutions using the latest AI and digital technologies at the device, care pathway, and enterprise-level, helping clinicians deliver a more personal, precise, and human approach to care from diagnosis to treatment to recovery.” Simplifying and improving workflows GE HealthCare offers next-generation solutions and AI-enabled products to streamline workflows and increase efficiency to drive better patient care, clinical decisions or outcomes. The following workflow efficiency technologies will be showcased at the event: Clarify DL , 510(k) pending in the U.S., is a bone image reconstruction algorithm powered by AI that is designed to enhance bone SPECT image quality performance, an important factor in increasing diagnostic confidence.* nCommand Lite by IONIC Health empowers radiology staff to focus on patient care, while accessing the support needed through remote collaboration and scan assistance. nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT) and positron emission tomography/CT (PET/CT) scanning. True PACS and v7 PACS solution , now supports Blackford’s AI orchestration platform and selective 3 rd party AI based imaging applications, providing seamless integration of AI in the reading workflow to help radiologists and clinicians provide quick and accurate diagnosis for patients. 1 The collaboration enables True PACS and v7 PACS solution customers to directly acquire Blackford Analysis’ AI-enabled platform with a catalogue of third-party AI applications that span across various clinical area use cases, ranging from mammography to lung scans. 2 MR Max 3™ , a wireless syringeless power injector for gadolinium-based contrast media is compatible with multiple contrast bottle sizes, including 24-hour multiuse containers (Imaging Bulk Packaging). The syringeless injector enhances workflow efficiency, lowers plastic waste consumption, and enables contrast optimization through the use the efficient use of Imaging Bulk Packaging containers, thus further reducing overall departmental cost by reducing contrast waste. Caption Guidance™ is AI-driven technology powered by deep learning image analysis algorithms that guide users on how to adjust the ultrasound probe. The software provides real-time, step-by-step instructions to ensure that the cardiac ultrasound images captured meet the diagnostic standard. Venue Sprint™ , a portable system in a tablet form, and the latest Venue family solution offering maximum portability and advanced capabilities for high-quality scanning and support at the point of care. Venue family ultrasound systems will also integrate wireless Vscan Air dual-probes and have access to Caption Guidance. Vscan Air SL handheld ultrasound system now features Caption AI, including Caption Interpretation AutoEF software, which automatically calculates a left ventricular ejection fraction (LVEF)—an important measure of heart function. In addition, Digital Tools for Vscan Air offers key tools to securely store and share images in the cloud. At RSNA, GE HealthCare will launch a new trial of Digital Tools for both existing and new Vscan Air users to evaluate new software. Precise and personalized care GE HealthCare strives to support health systems by delivering a personalized care pathway for each patient. GE HealthCare’s integrated cancer care products leverage digital, AI and our suite of innovative solutions along with imaging technologies and radiopharmaceuticals. These components are designed to enhance diagnoses, drive productivity, increase value, speed and efficiency, and improve overall patient health. At the event, GE HealthCare has several new oncology technologies that help provide personalized care: Aurora , 510(k) pending in the U.S, is a new dual head SPECT/CT, designed to help clinicians solve operational and diagnostic challenges as well as develop personalized approaches for better patient outcomes. It integrates deep learning image reconstruction and a collection of advanced CT clinical and effortless workflow solutions designed to help support better patient care.* GE HealthCare and RadNet recently announced a strategic collaboration that will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to further the innovation, commercialization, and adoption of AI in imaging. Together, GE HealthCare and DeepHealth aim to create SmartTechnology™ solutions that harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain to improve speed, clinical accuracy, operational efficiency, and elevate patient care. Senographe Pristina Via is an advanced mammography system that introduces innovative features designed to support technologist workflow and streamline the image acquisition process. CareIntellect for Oncology is a new cloud-first application that brings together multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. This solution also surfaces relevant data allowing care teams to quickly understand disease progression and flag potential deviations from the treatment plan to help the clinician determine next steps and inform proactive interventions. The application is planned to be available in the U.S. in 2025, initially focusing on prostate and breast cancer. The company aims to quickly expand into new disease types and care areas. Tampa General Hospital and UT Southwestern Medical Center will be early evaluators of CareIntellect for Oncology, and integration is already underway. In addition, theranostics is a rapidly growing field of molecular imaging leveraging radiotracers and diagnostic imaging equipment including PET and SPECT systems to precisely diagnose and monitor disease for the targeted delivery of therapy to patients. These therapeutic and diagnostic technologies work together to provide a personalized, highly precise, patient-centric approach to medical diagnosis and treatment. “Cancer care requires a personalized approach across the care continuum – from early detection and diagnosis, to planning, intervention and monitoring – to help improve patient outcomes,” said Roland Rott, president and CEO of Imaging at GE HealthCare. “Because of our comprehensive solutions and expertise in the healthcare industry, GE HealthCare is uniquely positioned to support every step of the theranostics care pathway while helping solve diagnosis challenges and develop personalized approaches.” GE HealthCare has recently announced new theranostics-related innovations including: MINItrace Magni (MI) is helping expand access to tracer production programs and making theranostics more accessible by delivering a compact, cost-effective cyclotron capable of reliable, in-house PET tracer and radiometal production with solid target technology. 3 Omni Legend now with 21 cm configuration is designed to evolve with healthcare system needs across care areas, including shorter scan times and lower doses without compromising image quality in oncology, support for increasing PET amyloid imaging in Alzheimer's diagnosis and treatment follow up in neurology, and cardiac diagnostics. It accommodates a range of tracers including fast decay and emerging tracers in cardiology. These capabilities are further enhanced with Precision DL, an innovative deep learning-based image processing software that is engineered to provide increased small, low-contrast lesion detectability compared to our conventional Time-of-Flight PET/CT scanner i . Flyrcado™ (F18 Flurpiridaz) injection is a first of its kind approved by U.S. FDA positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the enhanced detection of coronary artery disease (CAD). Flyrcado delivers higher diagnostic efficacy in patients with known or suspected CAD, compared to SPECT MPI, the predominant procedure used in nuclear cardiology today. GE HealthCare’s MIM Software received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to perform absorbed dose calculation of radionuclides using a Monte Carlo method. With this clearance, Monte Carlo dosimetry via the Dose Planning Method (DPM) will be available for use with MIM SurePlan MRT , MIM Software’s comprehensive solution. This vendor agnostic technology turns the otherwise cumbersome process of performing dosimetry into a clinically realistic process via automation and standardization. In just a few clicks, and with built-in guidance, users can review absorbed doses. Additional new products that will be demonstrated in the booth: Versana Premier is a multi-purpose, budget-friendly ultrasound system equipped with automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy. The system includes Digital Expert Connect, allowing users to easily collaborate virtually with colleagues across their network. True Enhance DL on Revolution Ascend platform is a dedicated Deep Neural Network (DNN) designed to increase contrast to support confident diagnoses in CT exams. The AI-based solution provides clinicians a simple workflow and incredible CT image quality. TrueFidelity DL on Revolution Apex and Revolution Ascend platforms is an image reconstruction technology that uses a Deep Neural Network to generate high-def, low-noise CT images with exceptional sharpness and low-contrast detectability with customer-preferred noise texture, at the same dose. 4 This includes cardiac images, helping reduce noise and increase image sharpness. SIGNA™ MAGNUS is an FDA 510(k) cleared head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems. 5 For more information on GE HealthCare and these innovative solutions at RSNA, visit Booth 7330, our press kit , or the RSNA 2024 events page . INDICATIONS AND USAGE OF FLYRCADO™: Indications and Usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and Precautions Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. For full prescribing information, click here . For important safety information, please click here . About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on LinkedIn , X , Facebook , Instagram , and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information. 1 True PACS is a solution which contains Universal Viewer, Enterprise Archive, Centricity Universal Viewer ZeroFootprint Client, Blackford AI Orchestrator and 3rd party clinical AI apps. 2 All clinical applications are not available in all countries. 3 MINItrace disclaimer: Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. 4 Image quality comparisons were evaluated by phantom tests of MTF, SSP, axial NPS, standard deviation of image noise, CT Number accuracy, CNR, and artifact analysis. Additionally, LCD was demonstrated in phantom testing using a model observer with the head and body MITA CT IQ Phantoms (CT191, CT189 The Phantom Laboratory). DLIR-H and ASiR-V reconstructions were performed using the same raw data. 5 510(k) cleared. Not CE marked. Not available for sale in any region. * 510(k) Pending at the U.S. FDA. Not Available for Sale in the United States. Not all products and solutions are available in all countries. Please contact your GE HealthCare representative to confirm availability. i At matched scan time and injected dose. Detectability using clinical data with an inserted 8 mm diameter liver lesion of known location and 2:1 contrast using a CHO model observer, comparing SNR from Omni Legend 32 cm with QCHD and Precision DL to SNR from Discovery™ MI 25 cm with QCFX.